MD Anderson Partners with AI Firm to Speed Cancer Diagnosis

In a significant step for cancer care, The University of Texas MD Anderson Cancer Center has entered a strategic partnership with the artificial intelligence company SOPHiA GENETICS. Announced on January 7, 2026, the collaboration aims to build new diagnostic tools that use AI to interpret complex genetic data more quickly and accurately. The core of the effort is the joint development of an advanced genomic test, powered by SOPHiA's cloud-based DDM platform, designed to turn intricate molecular information into clear guidance for doctors. \n\nDonna Hansel, M.

D. , Ph. D. , who leads the Pathology and Laboratory Medicine division at MD Anderson, explained the necessity of the move.

'Cancer research has progressed quickly, and we now have access to more health data than ever,' Hansel said. 'Working with SOPHiA GENETICS shows how our laboratory is integrating advanced analytics and AI to make sense of this complex information. ' The partnership will focus on tracking how tumors change over time and improving how patients are matched with clinical trials. \n\nFor SOPHiA GENETICS, the alliance with a premier institution like MD Anderson serves as a major endorsement.

The company's stock price rose more than 4% following the news. Philippe Menu, M. D. , Ph.

D. , the firm's Chief Product and Medical Officer, stated the platform is intended to 'enable new discoveries and accelerate breakthroughs' so patients worldwide can benefit. The work will be led at MD Anderson by researchers Shashikant Kulkarni, Ph. D.

, and J. Bryan, M. D. \n\nThe initiative addresses a central challenge in modern oncology: the overwhelming volume of data that can slow down treatment decisions.

By applying AI to data types like RNA-sequencing, the teams hope to reduce the time from analysis to actionable insight from weeks to mere hours, potentially offering patients more personalized and timely care.

Source: Webpronews